{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T13:59:12Z","timestamp":1775397552435,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"crossref","award":["Vici grant 09150181910040"],"award-info":[{"award-number":["Vici grant 09150181910040"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The world is currently dominated by the Corona Virus Disease 2019 (COVID-19) pandemic. Besides the obvious concerns about limitation of virus spread and providing the best possible care to infected patients, a concomitant concern has now arisen in view of a putative link between the use of certain drugs, such as Renin-Angiotensin System (RAS) inhibitors and ibuprofen, and an increased risk for COVID-19 infection. We here discuss this concern in relation to headache treatment and conclude that, based on current evidence, there is no reason to abandon treatment of headache patients with RAS inhibitors or ibuprofen.<\/jats:p>","DOI":"10.1186\/s10194-020-01106-5","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T18:03:33Z","timestamp":1587837813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Headache medication and the COVID-19 pandemic"],"prefix":"10.1186","volume":"21","author":[{"given":"Antoinette","family":"MaassenVanDenBrink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. H. Jan","family":"Danser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,25]]},"reference":[{"key":"1106_CR1","doi-asserted-by":"crossref","unstructured":"Panati K, Narala VR (2020) COVID-19 outbreak: an update on therapeutic options. SN Compr Clin Med In Press","DOI":"10.1007\/s42399-020-00264-6"},{"key":"1106_CR2","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8:e21","journal-title":"Lancet Respir Med"},{"issue":"6965","key":"1106_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li W et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426(6965):450\u2013454","journal-title":"Nature"},{"key":"1106_CR4","doi-asserted-by":"publisher","unstructured":"Danser, AHJ, Epstein M, Batlle D (2020) Renin-Angiotensin System Blockers and the COVID-19 Pandemic: at present there is no evidence to abandon Renin-Angiotensin System Blockers. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15082.","DOI":"10.1161\/HYPERTENSIONAHA.120.15082"},{"issue":"Suppl 3","key":"1106_CR5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/head.13375","volume":"58","author":"E Loder","year":"2018","unstructured":"Loder E, Rizzoli P (2018) Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018. Headache 58(Suppl 3):218\u2013229","journal-title":"Headache"},{"issue":"9","key":"1106_CR6","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s11606-013-2433-1","volume":"28","author":"TA Shamliyan","year":"2013","unstructured":"Shamliyan TA et al (2013) Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med 28(9):1225\u20131237","journal-title":"J Gen Intern Med"},{"issue":"1","key":"1106_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-019-1010-3","volume":"20","author":"LM Pomes","year":"2019","unstructured":"Pomes LM et al (2019) Optimising migraine treatment: from drug-drug interactions to personalized medicine. J Headache Pain 20(1):56","journal-title":"J Headache Pain"},{"issue":"1","key":"1106_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1161\/HYPERTENSIONAHA.119.14071","volume":"75","author":"P Serfozo","year":"2020","unstructured":"Serfozo P et al (2020) Ang II (angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (Prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent. Hypertension 75(1):173\u2013182","journal-title":"Hypertension"},{"issue":"4","key":"1106_CR9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1124\/pr.118.017129","volume":"71","author":"LB Arendse","year":"2019","unstructured":"Arendse LB et al (2019) Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure. Pharmacol Rev 71(4):539\u2013570","journal-title":"Pharmacol Rev"},{"issue":"20","key":"1106_CR10","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM et al (2005) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111(20):2605\u20132610","journal-title":"Circulation"},{"key":"1106_CR11","doi-asserted-by":"crossref","unstructured":"Soler MJ et al (2009) Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Ren Pysiol 296(2):F398\u2013F405","DOI":"10.1152\/ajprenal.90488.2008"},{"key":"1106_CR12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.yjmcc.2016.05.012","volume":"97","author":"X Wang","year":"2016","unstructured":"Wang X et al (2016) The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang (1-7)-mas axes in pressure overload-induced cardiac remodeling in male mice. J Mol Cell Cardiol 97:180\u2013190","journal-title":"J Mol Cell Cardiol"},{"key":"1106_CR13","doi-asserted-by":"publisher","first-page":"i2610","DOI":"10.1136\/bmj.i2610","volume":"353","author":"T Kurth","year":"2016","unstructured":"Kurth T et al (2016) Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ 353:i2610","journal-title":"BMJ"},{"issue":"2","key":"1106_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000375362","volume":"131","author":"W Qiao","year":"2015","unstructured":"Qiao W et al (2015) Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology 131(2):97\u2013106","journal-title":"Cardiology"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01106-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-020-01106-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01106-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T23:05:58Z","timestamp":1619305558000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-020-01106-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,25]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1106"],"URL":"https:\/\/doi.org\/10.1186\/s10194-020-01106-5","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,25]]},"assertion":[{"value":"2 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NA","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have seen and approved the final version of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NA","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}